acute T-lymphocyte leukemia or T cell lymphoblastic lymphoma
Conditions
Interventions
treatment group 1:Chidamide + HMAs + Venetoclax+Dex+VP16+Peg-Asp
Sponsors
Children's Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. The age of first visit is 0-18 years, male and female; 2. Children with acute T-lymphocyte leukemia (T-ALL) or T cell lymphoblastic lymphoma (T-NHL) confirmed by pathology (2008 WHO classification of hematopoiesis and lymphoid tissue tumors); . 3. Patients who had relapsed after at least one previous systemic therapy failure (refractory) or remission (including extramedullary relapse); 4. ECOG status scores were 0-3; 5. Life expectancy =3 months; 6. No serious heart, lung, liver or Kidney Diseases; 7. Capable of understanding and willing to sign this informed consent form. And has a full understanding of the purpose and significance of this test, and is willing to comply with the test program.
Exclusion criteria
Exclusion criteria: 1. Children with other tumors; 2. Children with severe concomitant disease, children with Severe Resistance to chemotherapy regimens (multiple malformations, heart disease, metabolic disorders, etc.); 3. Children with a history of mental illness that may prevent them from completing treatment; 4. Children with allergies to drugs or the same compounds in the combination regimens; 5. Children judged unfit to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission;partial remission;Minimal residual disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| event-free-survival;relapse-free-survival;overall survival;complete remission with incomplete bloodcount recovery; | — |
Countries
China
Contacts
Public ContactHu Shaoyan
Children's Hospital of Soochow University
Outcome results
None listed